Canaccord steps to sidelines on Sarepta

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT -3.1%) falls as Canaccord downgrades the shares to Neutral from Buy.

"We still predict eventual clinical/commercial success, but feel there is major near-term uncertainty in eteplirsen's regulatory timelines," analyst Ritu Baral notes.

Long story short: Canaccord likes the DMD treatment's efficacy and safety profile but doesn't necessarily like the confirmatory trial ambiguity.

Price target is still $20.